Rocket Pharmaceuticals(NASDAQ) RCKT

Rocket Pharmaceuticals makes medicines for rare heart and blood diseases. These treatments fix genetic causes of sickness in children and adults. The company helps people with illnesses that have few other options.

Treating Rare Genetic Conditions

• KRESLADI: FDA-approved gene therapy for children with severe leukocyte adhesion deficiency-I; designed for patients who lack a matching sibling donor for a bone marrow transplant.
• Cardiovascular Pipeline: Investigative gene therapies targeting inherited heart diseases such as Danon disease and various forms of cardiomyopathy.
• AAV Manufacturing: Internal facility in New Jersey that produces materials for discovery and clinical trials; supports the development of adeno-associated virus genetic medicines.

Steering Toward the Heart

• Received accelerated FDA approval for KRESLADI in March 2026 to treat a rare immune system disorder.
• Sold a Rare Pediatric Disease Priority Review Voucher for $180 million in June 2026 to provide non-dilutive capital.
• Reorganized operations in July 2025 to prioritize cardiovascular programs and reduced the workforce by approximately 30%.
• Resumed dosing in the pivotal Phase 2 Danon disease study in August 2025 after resolving a clinical hold.

In-House Science and Expertise

The company operates a 103,720 square foot manufacturing facility in New Jersey to control its production process. Its leadership team has a history of securing over 20 drug approvals across international markets.

The Latest Financial Facts

• Net income was $75.6 million for the six months ended June 30, 2026, compared to a net loss of $130.3 million in the same period of 2025.
• Revenue was zero for the six months ended June 30, 2026, as the company prepares for its first commercial launch.
• Research and development expenses were $61.0 million for the six months ended June 30, 2026, compared to $78.6 million in the prior-year period.
• The company held $283.7 million in cash, cash equivalents, and investments as of June 30, 2026.

Bottom Line

Rocket Pharmaceuticals has transitioned into a commercial-stage company while focusing its research on inherited heart diseases. This strategic shift aims to create value through a specialized portfolio of genetic medicines for patients with limited options.